Avataar’s B2B Tech companies include InsuranceDekho, India’s leading B2B Insurtech distribution company and ElasticRun, India’s leading Rural Commerce company.
LIGHTSPEED TRADING PLATFORM SOFTWARE
Avataar has partnered with India’s leading B2B SaaS companies, including media software unicorn Amagi, India’s first SaaS IPO and global leader in travel & hospitality RateGain, SaaS unicorn for wellness industry Zenoti and Retail CRM & Loyalty Capillary. Since its inception in 2014, the startup has been recognized as the best Doctor Productivity Software in India and has introduced several products such as EMR, Drug-to-Drug Interactions (DDI), Mobile EMR, AI-powered SmartScan, and Doctor Insights Dashboard, among others.Īvataar Venture Partners is an Early Growth stage fund focused on helping B2B Tech & SaaS companies accelerate their scaling journey.
LIGHTSPEED TRADING PLATFORM SERIES
The company’s current Series C funding round saw participation from its marquee existing investors, which is a testament to their trust in the health-tech startup.
In 2022, HealthPlix had secured USD 2mn in debt funding from Blacksoil Ventures. And in this moment of truth, the ONLY solution that doctors turn to for assistance is HealthPlix.” This intera ction is the moment of truth, where $100 billion of annual healthcare spend is decided. It is during doctor’s interaction with patients that health decisions get made, diagnostic tests get prescribed, medicines get chosen, surgical procedures get planned, and hospital referrals get made. ”Ĭommenting on the occasion, Chaitanya Raju, Executive Director, HealthPlix Technologies said, “Doctors are at the core of healthcare delivery. We’d be the first health-tech startup in India to secure Series C funding in 2023. Avataar Venture Partners and SIG Venture Capital share our passion and the doctor-first ethos, and we are delighted to be partnering with them. With these new funds, we aim to cater to 200-250Mn more patient lives in an 18-month time frame. Today, we serve 2.5% of the entire Indian population. At HealthPlix, our vision is to drive better Health Outcomes at Population level. Sharing his vision, Sandeep Gudibanda, CoFounder & CEO, HealthPlix Technologies said, “We are a 100% DOCTOR FIRST firm and that ethos has earned us significant TRUST from doctors. ‘’We invested in HealthPlix to help further the team’s vision of being the active catalyst for technology adoption in healthcare by allowing doctors to be more productive, thereby driving better outcomes for patients.’ ’ says Bhavanipratap Rana, Investment Advisor to SIG Venture Capital. Investment Advisor to Avataar Venture Partners We have seen many business models that have failed to scale in the Health-tech ecosystem and we believe that Sandeep has built a great team to deliver on HealthPlix promise”, says Mohan Kumar,
“HealthPlix approach of using Doctor as the focal point and delivering value to other stakeholders like Patients, Pharma brands, Pharmacies and Diagnostic labs is unique and differentiated. By 2024, the rapidly growing doctor base on Healthplix will include 25K+ doctors treating 15 percent of the entire population. HealthPlix currently empowers 10K+ doctors who treat 2.5 percent of the entire Indian population and is advancing national health missions, such as Ayushman Bharat Digital Mission (ABDM). Leading the health-tech segment, HealthPlix’s unique approach puts doctors first and solves for their pain points. The proceeds from this round of funding will be used to ramp up doctor first product innovation, enhance the technology stack and scale user acquisition efforts.Ī significant percentage of the Indian population suffers from chronic diseases and several health- tech startups have emerged to serve their needs. The funding round marks the first health-tech growth stage investment done by venture capitalists in 2023. HealthPlix Technologies – India’s most trusted and secure doctor software brand today announced the closure of $22million funding in Series C led by Avataar Venture Partners, SIG Venture Capital and existing investors.
0 kommentar(er)
